- Home
- MMSI vs PTGX Comparison
MMSI vs PTGX Comparison
Compare MMSI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MMSI | PTGX |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | 7400 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 5.4B |
| IPO Year | 1990 | 2016 |
Fundamental Metrics
Financial Performance| Metric | MMSI | PTGX |
|---|---|---|
| Price | $82.20 | $81.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $106.13 | $93.00 |
| AVG Volume (30 Days) | 730.1K | ★ 863.4K |
| Earning Date | 02-24-2026 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.95 | 0.72 |
| Revenue | ★ $1,477,128,000.00 | $209,217,000.00 |
| Revenue This Year | $13.53 | N/A |
| Revenue Next Year | $6.30 | $288.98 |
| P/E Ratio | ★ $41.18 | $117.67 |
| Revenue Growth | ★ 11.41 | N/A |
| 52 Week Low | $78.12 | $33.70 |
| 52 Week High | $111.45 | $96.54 |
Technical Indicators
Market Signals| Indicator | MMSI | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 40.07 | 43.54 |
| Support Level | $85.70 | $78.75 |
| Resistance Level | $94.75 | $87.44 |
| Average True Range (ATR) | 3.16 | 3.01 |
| MACD | -1.05 | -0.27 |
| Stochastic Oscillator | 15.30 | 36.81 |
Price Performance
Historical ComparisonAbout MMSI Merit Medical Systems Inc.
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.